SMARCA4 ‐deficient rhabdoid tumours show intermediate molecular features between SMARCB1 ‐deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type-Reference-Cited by-同舟云学术

SMARCA4 ‐deficient rhabdoid tumours show intermediate molecular features between SMARCB1 ‐deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type

Published:2021-06-23 Issue:1 Volume:255 Page:1-15
ISSN:0022-3417
Container-title:The Journal of Pathology
language:en
Short-container-title:J. Pathol.

Author:

Andrianteranagna Mamy¹²³,Cyrta Joanna⁴,Masliah‐Planchon Julien⁵,Nemes Karolina⁶,Corsia Alice¹,Leruste Amaury¹,Holdhof Dörthe⁷⁸^ORCID,Kordes Uwe⁷,Orbach Daniel⁹,Corradini Nadège¹⁰,Entz‐Werle Natacha¹¹,Pierron Gaëlle⁵,Castex Marie‐Pierre¹²,Brouchet Anne¹³,Weingertner Noëlle¹⁴,Ranchère Dominique¹⁵,Fréneaux Paul⁴,Delattre Olivier⁵,Bush Jonathan¹⁶^ORCID,Leary Alexandra¹⁷¹⁸,Frühwald Michael C⁶,Schüller Ulrich⁷⁸¹⁹,Servant Nicolas²³²⁰,Bourdeaut Franck¹⁹^ORCID

Affiliation:

1. INSERM, U830, Pediatric Translational Research PSL Research University, Institut Curie Paris France

2. INSERM, U900 Paris France

3. MINES ParisTech PSL Research University, CBIO‐Centre for Computational Biology Paris France

4. Department of Pathology Institut Curie, PSL Research University Paris France

5. Genetics Unit, Department of Tumor Biology Institut Curie, PSL Research University Paris France

6. Paediatrics and Adolescent Medicine, Swabian Children's Cancer Center University Medical Center Augsburg Augsburg Germany

7. Department of Pediatric Hematology and Oncology University Medical Center, Hamburg‐Eppendorf Hamburg Germany

8. Research Institute Children's Cancer Center Hamburg Hamburg Germany

9. SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer) PSL Research University, Institut Curie Paris France

10. Centre Léon Bérard, Institut d'Hématologie et d'Oncologie pédiatrique Lyon France

11. Pediatric and Adolescent Oncology, IHOP, Centre Léon Bérard Lyon France

12. Department of Pediatric and Adolescent Unity Oncology Toulouse University Hospital Toulouse France

13. Department of Pathology Insititut Universitaire du Cancer de Toulouse‐Oncopole Toulouse France

14. Department of Pathology Strasbourg University Hospital Strasbourg France

15. Department of Pathology Centre Léon Bérard Lyon France

16. Division of Anatomical Pathology, British Columbia Children's Hospital and Women's Hospital and Health Center Vancouver BC Canada

17. Gynecological Cancer Unit, Department of Medicine Gustave Roussy Villejuif France

18. INSERM U981, Gustave Roussy Villejuif France

19. Institute of Neuropathology University Medical Center, Hamburg‐Eppendorf Hamburg Germany

20. Institut Curie, PSL Research University Paris France

Funder

Institut National Du Cancer

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/path.5705

Reference63 articles.

1. Extracranial rhabdoid tumours: what we have learned so far and future directions

2. Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system

3. Clinical and genetic risk factors define two risk groups of extracranial malignant rhabdoid tumours (eMRT/RTK)

4. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer

5. Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of cancer predisposition syndrome in children and adolescents with very rare tumours;EJC Paediatric Oncology;2023-12

2. NUT carcinoma and thoracic SMARCA4‐deficient undifferentiated tumour: facts and controversies;Histopathology;2023-10-24

3. Imaging and multi-omics datasets converge to define different neural progenitor origins for ATRT-SHH subgroups;Nature Communications;2023-10-20

4. BRG1 establishes the neuroectodermal chromatin landscape to restrict dorsal cell fates;2023-06-24

5. Importance of pharmacologic considerations in the development of targeted anticancer agents for children;Current Opinion in Pediatrics;2022-12-23